SCHEMBL567835

SCHEMBL567835

[2H]C([2H])([2H])[Mg]I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28534036 0.78
SCHEMBL1072 0.68
SCHEMBL29358815 0.56
SCHEMBL4904203 0.56
Iodomethane SCHEMBL87147 0.54
Iodomethane SCHEMBL118500 0.54
Iodomethane SCHEMBL799995 0.54
Iodomethane SCHEMBL28473371 0.50
Fluoromethane SCHEMBL28308915 0.50
SCHEMBL495780 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
US-20260138978-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIV (US) 2026-05-21 US disclosed
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-12612412-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
EP-4709719-A1 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS Modulo Bio, Inc. (US) 2026-03-18 EP disclosed
US-12545662-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2026-02-10 US disclosed
EP-4678641-A1 QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF Shanghai Helioson Pharmaceutical Co., Ltd. (CN) 2026-01-14 EP disclosed
EP-4667464-A1 AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR Cyrus Therapeutics Inc. (KR) 2025-12-24 EP disclosed
US-20250367158-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARM INC (US) 2025-12-04 US disclosed
US-20090099140-A1 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof BIOXELL S.P.A. (IT) 2009-04-16 US disclosed
EP-1879596-A4 20-ALKYL, GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF BIOXELL SPA (IT) 2009-01-21 EP disclosed
WO-2008043857-A2 NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY BIOXELL SPA (IT) 2008-04-17 WO disclosed
WO-2008034908-A2 USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS BIOXELL SPA (IT) 2008-03-27 WO disclosed
EP-1879596-A1 20-ALKYL, GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF Bioxell S.p.a. (IT) 2008-01-23 EP disclosed
WO-2006102647-A1 20-ALKYL, GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF BIOXELL S.P.A. (IT) 2006-09-28 WO disclosed
WO-2004035517-A1 SPECIFIC MARKERS OF LIPID PEROXIDATION INSERM (FR) 2004-04-29 WO disclosed
EP-1411041-A1 Specific markers of lipid peroxidation INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2004-04-21 EP disclosed
US-6004905-A Hyperabas: biologically active abscisic acid analogs with unsaturated carbon substituents at the 8'-methyl or 9'-methyl carbon atoms NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1999-12-21 US disclosed
WO-1997023441-A1 HYPERABAS: BIOLOGICALLY ACTIVE ABSCISIC ACID ANALOGS WITH UNSATURATED CARBON SUBSTITUENTS AT THE 8'-METHYL OR 9'-METHYL CARBON ATOMS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1997-07-03 WO disclosed